S
Sensorion
Developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss
About Sensorion
Sensorion is a biopharmaceutical company founded in 2009, specializing in the development of therapies for debilitating inner ear disorders, such as hearing loss. The company operates in the healthcare and biotechnology markets, focusing on both clinical and preclinical stages of drug development. Sensorion's core clients include patients suffering from sudden sensorineural hearing loss and other inner ear conditions. The business model is centered around research and development, with revenue generated through the commercialization of its drug candidates and potential partnerships or licensing agreements. Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss and two preclinical gene therapy programs. The company also boasts a cutting-edge inner ear R&D platform, which underscores its commitment to scientific excellence and innovation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Montpellier, France
- Listing
- IPO 2015
- Employees
- 84
- Open positions
- 5
- Dealroom signal
- 74.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Hearing, Disability tech, Sustainable Development Goals
- Technology
- Connected Device
- Business model
- Manufacturing, SaaS
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jan 2026 | $66M | — | Sanofi · Invus · Redmile Group · Cormorant Asset Management | ↗ |
| POST IPO EQUITYOther financing | Apr 2024 | $17M | — | Sofinnova Partners · Invus · Redmile Group | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $24M | — | −$32M | -132.5% |
| 2025 | $0 | — | −$32M | — |
| 2024 | $0 | -100% | −$28M | — |
| 2023 | $5.2M | +17.9% | −$23M | -449.6% |
| 2022 | $4.4M | +20.6% | −$25M | -553.6% |
| 2021 | $3.7M | +74.1% | −$16M | -438.9% |
| 2020 | $2.1M | — | −$9.4M | -445.5% |
Growth signals
Latest recorded traffic for Sensorion is 7K monthly website visits, up 22.8% over the last three months. Sensorion's team grew 6.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Inserm Transfert Initiative- INInnoBio
Series B and later14 investors entered at this stage
Bpifrance
Alto Invest
Nyenburgh Holding B.V.
Novalis Lifesciences
Sofinnova Partners
WuXi AppTec
Invus
3SBio
Sonova Holding
Redmile Group
Sanofi
Cormorant Asset Management
Sphera Funds Management- CCCoastlands Capital
Other known investors1 additional known investor
Aquilo Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sensorion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sensorion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.